Navigation Links
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Date:9/24/2010

predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statement
'/>"/>
SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
4. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Trius Therapeutics Reports 2010 Second Quarter Results
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Sterlitech is proud to offer Synder ... PY, and PZ Polyacrylonotrile (PAN) membranes , as ... to be ideal for oil removal in wastewater ... process requirements where the presence of oils in ... on industrial wastewater discharge and quality requirements for ...
(Date:4/29/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced ... Biorem,s complete fiscal 2014 year-end financial statements and MD&A have been filed ... 2013 , 2014 , 2013 Revenue 3,968 ... Gross profit 1,326 , 1,703 , 2,231 ... , 3,377 , 4,562 Ebitda* 92 , ...
(Date:4/29/2015)... 2015 AlloSource ®, one of ... skin and soft-tissue allografts for use in surgical ... announced the launch of AlloSkin™ AC, an acellular ... Services (CMS) also moved AlloSkin™ RT, a meshed ... high-cost category for reimbursement. "AlloSource is ...
(Date:4/29/2015)... , April 29, 2015 /CNW/ - Northern Biologics Inc., ... Ventures, today announced an exclusive, strategic collaboration with ... Biologics received a US$30 million upfront cash payment. ... develop first-in-class therapeutic antibodies, and will have the ... the advancement of its portfolio. ...
Breaking Biology Technology:Sterlitech Offers New Ultrafiltration Membranes 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4AlloSource Announces New Possibilities In Wound Care 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... is scheduled to present a company overview at Citi,s 4th ... 1st at 10:40 a.m. EDT.To access the live audio webcast ... . Please connect to Rigel,s website several minutes prior to ...
... of Magnetic Resonance techniques including those used in hospital ... at the University of York. , Ultimately, the technique, ... shuttle, is expected to allow doctors to learn far ... at lower cost while increasing the range of medical ...
... Transform Diabetes CareIRVINE, Calif., March 26 On March ... its prestigious global diabetes research award. The award was ... Diabetes Monitoring Index Test , which uses glycated ... sugar in the body.(Photo: http://www.newscom.com/cgi-bin/prnh/20090326/LA89768 )Diabetes is ...
Cached Biology Technology:Transforming medical diagnosis with new scanning technology 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Greenland ice sheet can experience extreme melting even when temperatures ... Dr. Marco Tedesco, assistant professor in the Department of Earth ... His findings suggest that glaciers could undergo a self-amplifying ... halt. "We are finding that even if you don,t ...
... of us would love nothing more than to trick ourselves into ... a new brain imaging study reported in the November issue of ... just be a way. The key is to go with our ... findings suggest that a simple hormone-inspired pill could be the long-sought ...
... -- With salmonella-tainted ground turkey sickening more than 100 ... ability to detect outbreaks of food-borne illness and determine ... A new approach, reported online Oct. 14 in the ... collaborative team led by Cornell University scientists, will enable ...
Cached Biology News:Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3Simple gut hormone combo makes our brains think we're full 2New test can precisely pinpoint food pathogens 2
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Biology Products: